Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

Eliduderino Jul. 8 at 11:01 AM

$SILO Uh, I'm just gonna go find a cash machine. Looks like a climber.

0 · Reply

tyrus6 Jul. 7 at 3:10 PM

$ICU WHALE alert! 13G filing I see you there, Mitch! (Mitch has an itch. For ICU.) Here’s what I found on Mitchell P. Kopin (often filing with Intracoastal Capital LLC or alongside Daniel B. Asher), who recently disclosed a 9.99% stake in SeaStar Medical (ICU): --- 👤 Professional Background Founder of Cranshire Capital Advisors LLC (est. 1996) and currently President of Cranshire Capital LP, a private investment firm . **Former President of Downsview Capital, Inc.** . Education: Undergraduate degree from the U. of Illinois and graduate degree from Kellogg School of Management . --- 📈 Investment Strategy & History Mitchell Kopin frequently targets ~5–10% passive stakes in small-cap biotech, med-tech, and tech companies via Schedule 13G filings: Bone Biologics ($BBLG) – 9.99% stake (153K shares) filed June 27, 2025 . Ascent Solar ($ASTI) – 9.99% stake (318K shares) on June 27, 2025 . Processa Pharmaceuticals ($PCSA) – 9.99% on June 17, 2025 . Mitch also scored on $SILO

1 · Reply

aperzy20 Jul. 7 at 1:01 PM

$SILO big news!!! we will fly $MBIO $SONN

0 · Reply

Iiii1ii Jul. 7 at 12:31 PM

$SILO 1$+

0 · Reply

DonCorleone77 Jul. 7 at 12:31 PM

$SILO Silo Pharma expects preclinical study data on SPC-15 in Q3 Silo Pharma expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder. The final drug studies are an investigational new drug-enabling GLP-compliant toxicology and toxicokinetic animal study, and a U.S. Food and Drug Administration-requested 7-day safety and toxicology large animal study. Concurrently, a device study of the formulation-specific microchip-based nasal spray system used in SPC-15 is being conducted. Early data on SPC-15 indicated that its optimized patient safety profile and therapeutic delivery may provide additive benefits for combating stress-induced pathophysiology at both the behavioral and neural levels. Eric Weisblum, CEO of Silo, stated, "As we await pre-clinical data within the next 90 days, we currently anticipate initiating the IND application for SPC-15 before the end of the year, assuming positive data results. If submitted and approved, this will be a pivotal achievement along our path to first-in-human trials. If the FDA approves our IND within the 30-day review period, we could initiate a Phase 1 clinical trial before the end of 2026. Moving forward, we intend to seek the FDA's 505(b)(2) regulatory pathway for approval of SPC-15, a drug development route that can significantly shorten clinical timelines for FDA approval and reduce drug development costs."

0 · Reply

JL_TradeZ Jul. 7 at 12:24 PM

$SILO just confirmed preclinical PTSD trial data is coming in Q3 with an IND filing planned for 2025. They also locked in a 50/50 joint venture with HOTH to develop a new obesity therapy licensed from the VA. The float is only 6.2M, MACD just flipped, and volume finally kicked in Thursday. If this reclaims 0.675 with size, we could see it push toward 0.73 and 0.80 with room for more if volume stacks up. Targets: 0.73 / 0.80 / 0.93 Stop: 0.595

0 · Reply

NextBigRun Jul. 1 at 10:51 PM

$ATER’s setup is insane. Profitable brands, improving margins, insider buying, and AI-powered growth via AIMEE. The float is thin, the market cap is a joke, and shorts are still exposed. All it takes is one catalyst and this flies. Real company. Real upside. $REI $CLVR $SILO $CISO ‘!

1 · Reply

Green_dillo Jun. 30 at 4:31 PM

$SILO lfg 💦💦

0 · Reply

Abdul92z Jun. 26 at 9:32 PM

$SILO we need to clear .669 with volume to fly .. of course with news

1 · Reply

prakritim Jun. 26 at 4:28 PM

$SILO

0 · Reply

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 12 days ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 12 days ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Jun 11, 2025, 9:00 AM EDT - 26 days ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 4 weeks ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 6 weeks ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 7 weeks ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 7 weeks ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 7 weeks ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 7 weeks ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 2 months ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 2 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 3 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 4 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 4 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 5 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 5 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 6 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 7 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 7 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 18, 2024, 8:40 AM EST - 8 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Oct 31, 2024, 8:35 AM EDT - 8 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Sep 10, 2024, 6:35 AM EDT - 10 months ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Aug 14, 2024, 2:30 PM EDT - 11 months ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 7, 2024, 8:13 AM EDT - 11 months ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 18, 2024, 12:44 PM EDT - 1 year ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jun 26, 2024, 8:50 AM EDT - 1 year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 7, 2024, 8:18 AM EDT - 1 year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 6, 2024, 4:50 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 4, 2024, 8:41 AM EDT - 1 year ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

May 21, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 14, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Apr 23, 2024, 8:15 AM EDT - 1 year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Apr 10, 2024, 8:11 AM EDT - 1 year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Mar 18, 2024, 7:15 AM EDT - 1 year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Feb 28, 2024, 8:25 AM EST - 1 year ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Feb 14, 2024, 8:45 AM EST - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Feb 1, 2024, 10:00 AM EST - 1 year ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Jan 24, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Jan 4, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Dec 28, 2023, 8:25 AM EST - 1 year ago

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Nov 21, 2023, 8:01 AM EST - 1 year ago

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Nov 8, 2023, 8:11 AM EST - 1 year ago

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Oct 16, 2023, 8:11 AM EDT - 1 year ago

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Eliduderino Jul. 8 at 11:01 AM

$SILO Uh, I'm just gonna go find a cash machine. Looks like a climber.

0 · Reply

tyrus6 Jul. 7 at 3:10 PM

1 · Reply

aperzy20 Jul. 7 at 1:01 PM

$SILO big news!!! we will fly $MBIO $SONN

0 · Reply

Iiii1ii Jul. 7 at 12:31 PM

$SILO 1$+

0 · Reply

DonCorleone77 Jul. 7 at 12:31 PM

0 · Reply

JL_TradeZ Jul. 7 at 12:24 PM

0 · Reply

NextBigRun Jul. 1 at 10:51 PM

1 · Reply

Green_dillo Jun. 30 at 4:31 PM

$SILO lfg 💦💦

0 · Reply

Abdul92z Jun. 26 at 9:32 PM

$SILO we need to clear .669 with volume to fly .. of course with news

1 · Reply

prakritim Jun. 26 at 4:28 PM

$SILO

0 · Reply

prakritim Jun. 26 at 4:28 PM

$SILO banked too

0 · Reply

aperzy20 Jun. 26 at 12:24 PM

$SILO

0 · Reply

NewsAndFilings Jun. 26 at 12:09 PM

Yesterday's Recap: $SILO Letter of Intent to Form Joint Venture with $HOTH to Develop Obesity Treatment Targeting $16 Billion Global Market $MMMW Three Patent Pending Innovations Reducing Solar Desalination Cost to Be the Same as Tap Water in the $26 Billion Desalination Market

0 · Reply

psm18 Jun. 25 at 10:37 PM

$SILO Everybody come jump in the Silo with me ! There's psychedelics in here ! 🥴🤑👍💢😏🫡🦄

0 · Reply

Nbdy2u Jun. 25 at 3:49 PM

$SILO $RXRX these stocks will go up!!! The entire market today experienced a large dip due to Powell failing to cut interest rates once again, I don’t think Powell will be in the administration much longer!!! Keep holding and buy the dip!

0 · Reply

prakritim Jun. 25 at 3:42 PM

$SILO huge money for me here

1 · Reply

prakritim Jun. 25 at 3:41 PM

$SILO

0 · Reply

Arodrcp Jun. 25 at 2:08 PM

$SILO Exploring Psilocybin’s Role in End-of-Life Care | BJ Miller, M.D. (@bjmillermd) and Bridget Sumser, L.C.S.W. This clip is from episode # 354 of The Drive which was released on 6/23/25. In the full episode, we discuss: -How historical perspectives on death contrast with modern experiences of dying -How proactively engaging with the reality of death can avoid unnecessary suffering and promote a more peaceful ending -How psychedelics like psilocybin can unlock emotional breakthroughs and deepen connection for patients near the end of life -Lessons from the dying on how to live well -Much more Watch or listen (Ep. # 354) to the full episode on my website (peterattiamd.com/bjmillerandbri…) or your favorite podcast player.

0 · Reply

NewsAndFilings Jun. 25 at 2:02 PM

$SILO $HOTH Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market https://www.globenewswire.com/news-release/2025/06/25/3105102/0/en/Silo-Pharma-Enters-into-Letter-of-Intent-to-Form-Joint-Venture-with-Hoth-Therapeutics-to-Develop-Obesity-Treatment-Targeting-16-Billion-Global-Market.html

0 · Reply

Green_dillo Jun. 25 at 1:58 PM

$SILO lfg

0 · Reply

connorgthecyborg Jun. 25 at 1:39 PM

$HOTH $SILO

0 · Reply

defman Jun. 25 at 1:16 PM

$SILO Obesity drug. Americas new addiction. Let's see this thing jgo.

0 · Reply

Market Cap	2.76M
Revenue (ttm)	70,000.00
Net Income (ttm)	-4.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,271.43%
Debt to Equity Ratio	0.00

Volume	228,700
Avg Vol	1,198,242
Day's Range	N/A - N/A
Shares Out	4.48M
Stochastic %K	6%
Beta	0.29
Analysts	Strong Sell
Price Target	$10.00